Vishnu V. Muppuri (Mrs.) Co-Founder, Executive Director & COO for Indies Pharma Jamaica Limited Has Released The Following Twelve-Months Unaudited Financial Results For The Period Ending 31 October, 2023.
For the Twelve months ended October 31, 2023, Indies Pharma Jamaica Limited earned gross revenues of J$1,055 billion, 12.61% higher than the J$937 million in the prior comparable period of 2022.
Gross profit for the Twelve months increased to J$727 million, representing a 10.83% increase or J$71 million when compared to a similar period in 2022. This is attributable mainly to the enhanced customer loyalty towards the company’s product and service quality. The main contributor to our gross margin is increase in the sales which has provided us a favorable impact on our contribution and profitability.
Administrative expenses increased by 23.06% or J$86 million year over year principally due to a higher level of fleet vehicle maintenance, salaries, and royalty obligation.
The ‘Profit from Operations increased by 0.24% of J$283.5 million in 2023 when compared with $282.8 million during the same period of 2022. This increase in admin expenses also caused ‘Net Profit for the twelve months’ to decrease by 4.71% to J$210 million from J$220 million for the same twelve-month period of 2022.
In addition to the above, as of the last quarter of this fiscal year, the five-year zero corporate income tax (CIT) incentive period has come to an end. Going forward the company’s performance will now attract a CIT bracket of 12.5% over the next 5 years. Despite 12.5% CIT being applied during the last quarter of the current fiscal year, the company delivered the net profits almost the same as last year which resonates with the ethos of the company, stability, and consistency in delivering the positive yield to the investors.
Total assets at the end of the Twelve months stood at J$2.2 billion which represents an 8% increase or $158 million to the comparative period of 2022, the major contributor being the value increment in the intangible assets (Favorable) from J$379 million in 2022 to J$440 million in 2023 (J$61Million Movement).
Shareholders’ equity has increased by 5.14% this year to J$1.216 billion compared to J$1.156 billion in the prior period of 2022 and total liabilities increased by 11.13% in 2023 to J$990 million from J$891 million in 2022. The main contributing factor to the increase in total liability is the extension granted to occupied leased premises.
❖ Earnings per share (EPS) is S0.1578 for the twelve-months period in 2023 compared to $0.1656 for the same period in 2022.
Results For The Fourth Quarter Ended 31 October 2023
For the fourth quarter that ended October 2023, revenues increased by J$59 million (28.10%) to end at J$268 million from J$209 million in the corresponding periods of 2022. This is a result of the strong demand for the Indies Pharma products along with the strategies implemented to drive sales.
Gross profit for the quarter increased to $172 million which represented an increase of 25.05% or $34 million in comparison to $137 million for the previous quarter 2022. The main contribution came from our sales volume and value increment.
Other contributing factors are the robust approach taken in monitoring inventory and mitigating the writing-off of expired stock.
Administrative Expenses increased by 24.24% (J$22 million) to $116 million for the current quarter in comparison to $93.5 million in the corresponding quarter of the prior year.
Increased expenditures in several areas including Bioprist Royalty expenses, because of a change in accounting policy re the computation, accrual process, and booking of same. This increase was expected in this current year of adoption; however, this will normalize in the subsequent year.
Building maintenance & repairs, Admin & Drug permits and motor vehicle expenses were also contributory factors to the operating expenses (Opex) increase.
Net Profit for the three months has increased by 4.48% to J$34 million from J$33 million during the same three-month period in 2023 and 2022 respectively.
The $805 million bond attained in 2020 towards “Growth Capital” continues to remain on the books as we continue to grow the company through the organic development and approval of two new drugs at the USFDA for the United States Market.
As stated in our 2nd Quarter JSE filing, we have successfully submitted our very first ANDA – Abbreviated New Drug Application (generic drug dossier) on the 25 January 2023 at the USFDA. The same was accepted by the USFDA without any rejections or queries on the 24th of February 2023 with a gold date of approval as November 2023. Queries from the USFDA during this fourth quarter were uneventful and were effectively addressed and filed by us.
❖ Earnings per share (EPS) is $0.0258 during the fourth quarter of 2023 compared to $0.0248 for the same period in 2022.
The Company remains healthy, growth focused and continues to deliver and maintain a consistent upward trend in its performance and profitability to its shareholders.
For More Information CLICK THIS LINK